MAP2K7 and neoplasm: Tumor-bearing mice were subdivided into three cohorts, one untreated used as control, and two others receiving for a period of 20 days (D20) either Decitabine or MEK+BCL-XL inhibitors (MEK inhibitor: trametinib; BCL-XL inhibitor: ABT-737; Tables S7 and S8).